Eckert & Ziegler SE

Eckert & Ziegler: Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.

Eckert & Ziegler SE: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, buy

Eckert & Ziegler SE: Dr. Andreas Eckert, sell

Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023

Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply

Eckert & Ziegler SE: Dr. Harald Hasselmann, Allocation of 1,105 shares as part of management board remuneration (own shares of the issuer). This is a share-based remuneration with an automatic …

Eckert & Ziegler SE: Dr. Andreas Eckert, Allocation of 1,560 shares as part of management board remuneration (own shares of the issuer). This is a share-based remuneration with an automatic …

Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.

Eckert & Ziegler Completes Change of Legal Form to SE

Eckert & Ziegler Extends Ga-68 Activities in Japan

Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177

Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals

Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates

First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)

Eckert & Ziegler: Personnel Changes in the Management. Changes in the Executive Board and Supervisory Board.

Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes

Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023

Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials

Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG

Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets

Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.

Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225

Eckert & Ziegler Receives Award for Professional Training

Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma

Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients